Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2

12 October 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Cepharanthine is a natural of plant origin, and recently demonstrated to have anti-SARS-CoV-2 activity. In order to evaluate the other natural analogues as a potential COVID-19 drug, a total of 24 compounds resembling cepharanthine were extracted from the KNApSAcK database, and their binding affinities to supposed target proteins, namely, spike protein and main protease of SARS-CoV-2, NPC1, and TPC2, were predicted via molecular docking simulations. Selected analogues were further evaluated by a cell-based SARS-CoV-2 infection assay, and the efficacies of cepharanthine (IC50 1.90 uM) and tetrandrine (IC50 10.37 uM) were demonstrated. From a comparison of the docking conformations of these compounds, the diphenyl ester moiety of the molecules was suggested for a putative pharmacophore of the cepharanthine-analogues.

Keywords

Coronavirus
SARS-CoV
Molecular docking
Drug repurposing
Natural drug

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.